Larazotide vs Linaclotide
Head-to-head comparison of Larazotide (Larazotide acetate (AT-1001)) and Linaclotide (Linaclotide) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Larazotide | Linaclotide |
|---|---|---|
| Category | Gastrointestinal | Gastrointestinal |
| Full Name | Larazotide acetate (AT-1001) | Linaclotide |
| Molecular Weight | N/A | 1526.8 Da |
| Half-Life | short; designed for local gut action | Active locally; negligible systemic half-life |
| Amino Acids | 8 | 14 |
| Typical Dose | 0.5-4 mg TID (clinical studies) | 72-290 mcg once daily |
| Route | Oral | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 40 | 1200 |
| Research Status | Clinical | Clinical |
Larazotide Benefits
- ✓tight-junction-support
- ✓reduced-permeability
- ✓symptom-reduction
- ✓barrier-protection
Linaclotide Benefits
- ✓improves-bowel-movements
- ✓reduces-abdominal-pain
- ✓increases-intestinal-secretion
- ✓supports-transit
Larazotide Dosing
0.5-4 mg orally before meals in clinical trials|typically three times daily|short-course or chronic study protocols
Linaclotide Dosing
72 mcg PO daily|145 mcg PO daily|290 mcg PO daily
Larazotide Side Effects
- ⚠headache
- ⚠nausea
- ⚠abdominal discomfort
Linaclotide Side Effects
- ⚠diarrhea
- ⚠abdominal-pain
- ⚠bloating
Research Overview
Larazotide
Clinical and translational studies suggest larazotide can reduce antigen passage across the epithelium and improve gut barrier function. It is one of the better-known peptides for intestinal permeability and barrier-focused gastrointestinal therapy.
Linaclotide
Linaclotide has extensive clinical evidence for chronic idiopathic constipation and IBS-C, with consistent effects on stool frequency and abdominal symptom relief. Its mechanism is local GC-C activation in the gut with minimal systemic exposure.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.